# Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population

> **NCT04626024** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Baylor College of Medicine** · enrollment: 17 (actual)

## Conditions studied

- Chronic Myeloid Leukemia
- Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission
- Chronic Myeloid Leukemia in Remission

## Interventions

- **OTHER:** Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal
- **DRUG:** Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation

## Key facts

- **NCT ID:** NCT04626024
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-22
- **Primary completion:** 2028-11-15
- **Final completion:** 2028-11-15
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04626024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04626024, "Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04626024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*